1. Home
  2. DEA vs SPTX Comparison

DEA vs SPTX Comparison

Compare DEA & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Easterly Government Properties Inc.

DEA

Easterly Government Properties Inc.

HOLD

Current Price

$24.79

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

N/A

Current Price

$24.19

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DEA
SPTX
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
DEA
SPTX
Price
$24.79
$24.19
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$23.49
N/A
AVG Volume (30 Days)
344.0K
95.6K
Earning Date
04-27-2026
N/A
Dividend Yield
7.77%
N/A
EPS Growth
50.00
N/A
EPS
0.08
N/A
Revenue
$336,099,000.00
N/A
Revenue This Year
$5.41
N/A
Revenue Next Year
$3.33
N/A
P/E Ratio
$310.75
N/A
Revenue Growth
11.27
N/A
52 Week Low
$20.56
$17.59
52 Week High
$25.96
$24.65

Technical Indicators

Market Signals
Indicator
DEA
SPTX
Relative Strength Index (RSI) 50.12 67.88
Support Level $24.35 $18.72
Resistance Level $24.94 N/A
Average True Range (ATR) 0.57 1.27
MACD -0.06 0.25
Stochastic Oscillator 54.70 92.63

Price Performance

Historical Comparison
DEA
SPTX

About DEA Easterly Government Properties Inc.

Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Share on Social Networks: